CAMP
CAMP4 Therapeutics·NASDAQ
--
--(--)
--
--(--)
CAMP fundamentals
During Q4 2025, CAMP4 Therapeutics (CAMP) reported revenue of 348.00K, a YoY change of -46.63%. Net income was -40.28M, a YoY change of -203.37%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 350.00K -- | -- -- | -- -- | -- -- | 0 -100.00% | 652.00K -- | 858.00K -- | 1.50M -- | 795.00K -- | 348.00K -46.63% | 3.50M -- |
Sales and Services Revenue | 350.00K -- | 0 -- | 0 -- | 0 -- | 0 -100.00% | 652.00K -- | 858.00K -- | 1.50M -- | 795.00K -- | 348.00K -46.63% | 3.50M -- |
Operating Expenses | 12.69M -- | 13.48M -- | 12.88M -- | 12.66M -- | 13.52M +6.53% | 14.69M +8.98% | 13.96M +8.41% | 14.53M +14.71% | 14.45M +6.88% | 13.12M -10.64% | 56.05M -- |
Selling, General and Administrative Expenses | 2.87M -- | 2.81M -- | 3.13M -- | 3.27M -- | 3.81M +32.94% | 4.69M +66.61% | 3.81M +21.59% | 4.18M +27.77% | 4.60M +20.50% | 4.77M +1.64% | 17.36M -- |
General and Administrative Expenses | 2.87M -- | 2.81M -- | 3.13M -- | 3.27M -- | 3.81M +32.94% | 4.69M +66.61% | 3.81M +21.59% | 4.18M +27.77% | 4.60M +20.50% | 4.77M +1.64% | 17.36M -- |
Research and Development Expenses | 9.82M -- | 10.66M -- | 9.74M -- | 9.39M -- | 9.70M -1.19% | 10.00M -6.24% | 10.15M +4.17% | 10.34M +10.16% | 9.36M -3.57% | 8.36M -16.40% | 38.20M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 494.00K -- | 0 -- | -- -- |
Operating Income | -12.34M -- | -13.48M -- | -12.88M -- | -12.66M -- | -13.52M -9.55% | -14.03M -4.14% | -13.10M -1.75% | -13.03M -2.89% | -13.65M -1.00% | -12.78M +8.96% | -52.55M -- |
Non-Operating Income (Loss) | 642.00K -- | 486.00K -- | 423.00K -- | 86.00K -- | 32.00K -95.02% | 755.00K +55.35% | 667.00K +57.68% | 441.00K +412.79% | -1.45M -4625.00% | -27.51M -3743.44% | -27.85M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | -1.80M -- | -28.03M -- | -- -- |
Other Non-Operating Income (Loss) | -47.00K -- | -83.00K -- | 28.00K -- | -145.00K -- | -62.00K -31.91% | 145.00K +274.70% | 79.00K +182.14% | -12.00K +91.72% | -71.00K -14.52% | -188.00K -229.66% | -192.00K -- |
Net Interest Expense | -689.00K -- | -569.00K -- | -395.00K -- | -231.00K -- | -94.00K +86.36% | -610.00K -7.21% | -588.00K -48.86% | -453.00K -96.10% | -423.00K -350.00% | -710.00K -16.39% | -2.17M -- |
Interest Income | 689.00K -- | 569.00K -- | 395.00K -- | 231.00K -- | 94.00K -86.36% | 610.00K +7.21% | 588.00K +48.86% | 453.00K +96.10% | 423.00K +350.00% | 710.00K +16.39% | 2.17M -- |
Pretax Income From Continuing Operations | -11.70M -- | -12.99M -- | -12.45M -- | -12.58M -- | -13.48M -15.29% | -13.28M -2.22% | -12.43M +0.15% | -12.59M -0.09% | -15.10M -11.98% | -40.28M -203.37% | -80.40M -- |
Net Income | -11.70M -- | -12.99M -- | -12.45M -- | -12.58M -- | -13.48M -15.29% | -13.28M -2.22% | -12.43M +0.15% | -12.59M -0.09% | -15.10M -11.98% | -40.28M -203.37% | -80.40M -- |
Net Income Attributable to Owners of the Company | -11.70M -- | -12.99M -- | -12.45M -- | -12.58M -- | -13.48M -15.29% | -13.28M -2.22% | -12.43M +0.15% | -12.59M -0.09% | -15.10M -11.98% | -40.28M -203.37% | -80.40M -- |
Net Income Attributable to Common Stockholders | -11.70M -- | -12.99M -- | -12.45M -- | -12.58M -- | -13.48M -15.29% | -13.28M -2.22% | -12.43M +0.15% | -12.59M -0.09% | -15.10M -11.98% | -40.28M -203.37% | -80.40M -- |
Total Comprehensive Income | -11.70M -- | -12.99M -- | -12.45M -- | -12.58M -- | -13.48M -15.29% | -13.28M -2.22% | -12.43M +0.15% | -12.59M -0.09% | -15.10M -11.98% | -40.28M -203.37% | -80.40M -- |
Total Comprehensive Income Attributable to Owners of the Company | -11.70M -- | -12.99M -- | -12.45M -- | -12.58M -- | -13.48M -15.29% | -13.28M -2.22% | -12.43M +0.15% | -12.59M -0.09% | -15.10M -11.98% | -40.28M -203.37% | -80.40M -- |
Basic EPS | -29.21 -- | -- -- | -26.57 -- | -26 -- | -24.19 +17.19% | -0.66 -- | -0.62 +97.67% | -0.62 +97.62% | -0.55 +97.73% | -0.78 -18.18% | -2.57 -- |
Basic EPS from Continuing Operations | -29.21 -- | -- -- | -26.57 -- | -26 -- | -24.19 +17.19% | -- -- | -0.62 +97.67% | -0.62 +97.62% | -0.55 +97.73% | -- -- | -- -- |
Diluted EPS | -29.21 -- | -- -- | -26.57 -- | -26 -- | -24.19 +17.19% | -- -- | -0.62 +97.67% | -0.62 +97.62% | -0.55 +97.73% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -29.21 -- | -- -- | -26.57 -- | -26 -- | -24.19 +17.19% | -- -- | -0.62 +97.67% | -0.62 +97.62% | -0.55 +97.73% | -- -- | -- -- |
You can ask Aime
What were the key takeaways from CAMP4 Therapeutics's earnings call?What is the revenue and EPS growth rate for CAMP4 Therapeutics year over year?What guidance did CAMP4 Therapeutics's management provide for the next earnings period?What does CAMP4 Therapeutics do and what are its main business segments?What factors drove the changes in CAMP4 Therapeutics's revenue and profit?What is CAMP4 Therapeutics's latest dividend and current dividend yield?What is CAMP4 Therapeutics's gross profit margin?What is the market's earnings forecast for CAMP4 Therapeutics next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
